Status:
COMPLETED
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
Eligibility Criteria
Inclusion
- prostate cancer
- at least one bone metastasis
- receiving or about to receive androgen deprivation therapy (ADT)
Exclusion
- previous ADT failure
- previous or current treatment with another bone-protecting agent, chemotherapy or targeted therapy
- abnormal renal function
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
522 Patients enrolled
Trial Details
Trial ID
NCT00242567
Start Date
December 1 2005
End Date
January 1 2012
Last Update
May 7 2014
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Adelaide, Australia
2
Novartis Investigative Site
Brisbane, Australia
3
Novartis Investigative Site
Melbourne, Australia
4
Novartis Investigative Site
Port Macquarie, Australia